Compare Vanguard Information Technology Index Fund ETF (VGT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Information Technology Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Information Technology Index Fund ETF trades at $121.49, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| VGT | XBI | |
|---|---|---|
52-Week High | $125.77 | $164.28 |
52-Week Low | $83.59 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Information Technology ETF (VGT) trades at $121.60, up 1.12% with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from institutional accumulation and AI-driven technology sector strength, though RSI levels indicate potential near-term overbought conditions. Recent news highlights VGT's pure tech focus and outperformance versus broader tech ETFs.
VGT offers concentrated exposure to AI infrastructure leaders with strong institutional backing, but faces risks from sector concentration and valuation pressures. The ETF's momentum-driven returns depend on continued technology sector leadership, particularly in semiconductor and cloud computing segments where earnings growth remains robust.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
